Other management for recurrent thromboembolism in thrombotic antiphospholipid syndrome

Consider using statins in patients with thrombotic antiphospholipid syndrome and moderate to high risk of atherosclerotic complications (eg venous thromboembolism, stroke, acute myocardial infarction).

The role of systemic corticosteroids and immunomodulatory drugs in the treatment of thrombotic antiphospholipid syndrome and recurrent thromboembolism is uncertain. The only patient groups likely to benefit from these drugs are those with an additional indication (eg associated inflammatory connective tissue disease, such as SLE or Sjögren syndrome).

Refer any patient with suspected catastrophic antiphospholipid syndrome to hospital for immediate management. This complication usually occurs in people with known thrombotic antiphospholipid syndrome (ie a recurrence).

Note: Refer patients with suspected catastrophic antiphospholipid syndrome to hospital for immediate management.

For significant refractory thrombocytopenia, B cell–depleting therapies, such as rituximab, may be considered by some specialists.